editorialTop 10% cited
Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?
International Journal of Cardiology · 2002 · Vol. 85(2-3) · pp. 195–197
Nitric Oxide and Endothelin EffectsHeart Failure Treatment and ManagementPulmonary Hypertension Research and TreatmentsBosentanMedicineHeart failureEndothelin receptor antagonistCardiologyInternal medicineEndothelin receptorPlaceboEjection fractionReceptor
MeSH terms
BosentanAntihypertensive AgentsHeart FailureHospitalizationHumansSulfonamidesRandomized Controlled Trials as TopicTreatment OutcomeEndothelin Receptor Antagonists
Citations
292
FWCI
8.28
field-weighted impact
References
8
Percentile
98%
vs. same field & year
Citations per year
Cited by
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
European Heart Journal · 2009 · 3,846 citations
Guidelines for the diagnosis and treatment of pulmonary hypertension
European Respiratory Journal · 2009 · 1,291 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.